Pharmacokinetic and clinical evaluation of cefpirome in the pediatric field

  • Toyonaga Y
  • Yamori K
  • Sakaguchi N
 et al. 
  • 6


    Mendeley users who have this article in their library.
  • 2


    Citations of this article.


We conducted a pharmacokinetic and clinical study on cefpirome (HR 810, CPR), an aminothiazolylmethoxyiminoacetamido cephalosporin (ATOIC), and obtained the following results. 1. Concentrations in blood/excretion in urine. We studied pharmacokinetic in children upon intravenous bolus injections and 30-minute and 1-hour intravenous drip infusions in single dosages of 10, 20 and 40 mg/kg, and obtained virtually the same results as those found in adult subjects. Upon intravenous bolus injections, mean blood concentrations 30 minutes after administration of 10, 20, and 40 mg/kg were 26.1, 47.8, and 82.8 mug/ml, respectively, and half-lives were 1.13, 1.43, and 1.26 hours, respectively. Upon 30-minute intravenous drip infusion, mean blood concentrations on completion of the drip infusions of 10, 20, and 40 mg/kg were 43.2, 106.9, and 163.0 mug/ml, respectively, and half-lives were 1.15, 1.09, and 1.15 hours, respectively. In addition, upon 1-hour intravenous drip infusion, mean blood concentrations on completion of infusion were 27.1 mug/ml for 10 mg/kg and 47.5 mug/ml for 20 mg/kg, and half-lives were 1.09 and 1.40 hours, respectively. A clear dose response was observed at all dosages for either administration method. Mean excretion rates in urine in the first 8 hours after administration were 60.6-71.1% upon intravenous bolus injections of 10-40 mg/kg, and upon intravenous drip infusion, the values were 50.2-83.8% for administration of 10-40 mg/kg 6 or 7 hours after completion of drip infusion. 2. Concentrations in the cerebrospinal fluid. Penetration into the cerebrospinal fluid was studied in 2 subjects, and a concentration of 0.28-5.19 mug/ml was observed upon administration of 50 mg/kg, a moderate degree of penetration compared to the penetration of cephalosporins of group 5 studied up to now. 3. Clinical results. Evaluation of clinical effects of CPR on various types of bacterial infections was conducted in 56 subjects, excluding 3 subjects who had diseases which were excluded from the study. The breakdown was as follows: 3 cases of meningitis, 1 case of septicemia, 25 cases of bronchial pneumonia, 1 case each of tonsillitis and infection of the external acoustic meatus, 2 cases each of scarlet fever and phlegmon, 8 cases each of lymphadenitis and urinary tract infections, and 5 cases of staphylococcal scalded skin syndrome. Results of excellent or good were obtained in 54 subjects for an efficacy rate of 96.4%. There were 6 cases of mixed infections (2 cases of Haemophilus influenzae + Staphylococcus aureus, 1 case each of H. influenzae + Streptococcus pyogenes and H. influenzae + Branhamella catarrhalis, and 2 cases of H. influenzae + Streptococcus pneumoniae), 37 cases of single infections, 22 cases of Gram-positive cocci (12 cases of S. aureus, 4 cases of S. pyogenes, and 6 cases of S. pneumoniae), and 15 cases of Gram-negative bacilli (1 case each of B. catarrhalis, Proteus mirabilis, Haemophilus parainfluenzae, Pseudomonas fluorescens, 6 cases of H. influenzae and 5 cases of Escherichia coli). Causative bacteria were confirmed in 43 of 56 cases, eradication of the bacteria was observed during the course of the study in 40 cases, excluding 1 case each of single infections with S. aureus, S. pneumoniae, and P. fluorescens which were unevaluable, thus an eradication rate of 100% was obtained. From these clinical results according to individual types of bacteria isolated, it appears that CPR was effective in all cases except pneumonia resulting from S. pneumoniae, for a total of 42 of 43 cases with an efficacy rate of 97.7%. 4. Side effects and clinical laboratory findings. A study of safety was conducted on a total of 59 subjects, including 3 subjects with mycoplasmal pneumonia who were excluded. Only few cases of side effects were observed, with only 1 case of each drug fever and diarrhea. In clinical laboratory tests, elevated GOT and GPT and eosinophilia were observed to the same extent as for other group 5 cephalosporins, and an extremely small number of cases of abnormalities such as leukopenia and thrombocytosis was observed. The above results indicate that CPR, which has the outstanding antibacterial properties of group 5 cephalosporins, with an increased practical value against Enterococcus faecalis, and an antibacterial activity against S. aureus comparable to that of old-type cephem preparations, appears to be quite useful as a drug in the treatment of multiple bacterial infections and as replacement in cases where other antibacterial drugs are ineffective.

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • Yoshikiyo Toyonaga

  • Kazuko Yamori

  • Naoya Sakaguchi

  • Morimasa Sugita

  • Kenichi Kawamura

  • Kiwamu Seo

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free